Review



cytokines ifn γ  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Elabscience Biotechnology cytokines ifn γ
    Cytokines Ifn γ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 200 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Mouse+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pmc13683952-437-7-19
    Average 96 stars, based on 200 article reviews
    cytokines ifn γ - by Bioz Stars, 2026-11
    96/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Metabolomics combined with molecular docking and dynamics simulation to investigate the mechanism of action of Fibraurea recisa Pierre in the treatment of chronic urticaria
    Article Snippet: .. Centrifuge at 5,000 g for 10 min, take the supernatant for detection, and detect the expression of IL-4 (SEKR-0004, Solarbio, Beijing, China), IL-6 (SEKR-0005), IL-12 (E-EL-R0064c; Elabscience, TX, United States) and Interferon-γ (IFN-γ, E-EL-R0009, Elabscience) in skin tissues according to the instructions of the ELISA kit. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Metabolomics combined with molecular docking and dynamics simulation to investigate the mechanism of action of Fibraurea recisa Pierre in the treatment of chronic urticaria
    Article Snippet: .. Centrifuge at 5,000 g for 10 min, take the supernatant for detection, and detect the expression of IL-4 (SEKR-0004, Solarbio, Beijing, China), IL-6 (SEKR-0005), IL-12 (E-EL-R0064c; Elabscience, TX, United States) and Interferon-γ (IFN-γ, E-EL-R0009, Elabscience) in skin tissues according to the instructions of the ELISA kit. ..

    Article Title: Tinosporine alleviates collagen-induced arthritis in rats via modulating the gut microbiota-metabolome-immunity axis.
    Article Snippet: Background: Rheumatoid arthritis (RA) is an inflammation-mediated autoimmune disease.. Tinosporine (TIN), derived from Tinospora sinensis (Lour.). Merr. has significant anti-inflammatory and immunosuppressive effects.

    Article Title: Pharmacological Role of Capparis decidua (Forssk.) Edgew in Preventing Cyclophosphamide-induced Myelosuppression and Modulating Innate and Adaptive Immune Response
    Article Snippet: All the chemicals utilized during research work were of analytical grade and obtained from different sources; ie dexamethasone, nigrosine and nylon pellets from Sigma Aldrich (USA), cyclophosphamide from Pharmedic, Lahore (Pakistan), levamisole from ICI (Pakistan), ketamine from Global Pharmaceuticals (Pakistan) and xylazine from mylab, Bahawalpur (Pakistan). .. ELISA kits for Interferon-γ (Catalog No: E-EL-R0009), Interleukin-2 (Catalog No: E-EL-R0013), Immunoglobulin type G (Catalog No: E-EL-R0518) and type M (Catalog No: E-EL-R3016) while colorimetric assay kits for malondialdehyde (MDA; E-BC-K025-M), total superoxide dismutase (T-SOD; E-BC-K020-M), glutathione peroxidase (GSH-Px; E-BC-K096-M) and catalase (CAT; E-BC-K031-M) were purchased from Elabscience Biotechnology, USA. ..

    Colorimetric Assay:

    Article Title: Pharmacological Role of Capparis decidua (Forssk.) Edgew in Preventing Cyclophosphamide-induced Myelosuppression and Modulating Innate and Adaptive Immune Response
    Article Snippet: All the chemicals utilized during research work were of analytical grade and obtained from different sources; ie dexamethasone, nigrosine and nylon pellets from Sigma Aldrich (USA), cyclophosphamide from Pharmedic, Lahore (Pakistan), levamisole from ICI (Pakistan), ketamine from Global Pharmaceuticals (Pakistan) and xylazine from mylab, Bahawalpur (Pakistan). .. ELISA kits for Interferon-γ (Catalog No: E-EL-R0009), Interleukin-2 (Catalog No: E-EL-R0013), Immunoglobulin type G (Catalog No: E-EL-R0518) and type M (Catalog No: E-EL-R3016) while colorimetric assay kits for malondialdehyde (MDA; E-BC-K025-M), total superoxide dismutase (T-SOD; E-BC-K020-M), glutathione peroxidase (GSH-Px; E-BC-K096-M) and catalase (CAT; E-BC-K031-M) were purchased from Elabscience Biotechnology, USA. ..

    Multiple Displacement Amplification:

    Article Title: Pharmacological Role of Capparis decidua (Forssk.) Edgew in Preventing Cyclophosphamide-induced Myelosuppression and Modulating Innate and Adaptive Immune Response
    Article Snippet: All the chemicals utilized during research work were of analytical grade and obtained from different sources; ie dexamethasone, nigrosine and nylon pellets from Sigma Aldrich (USA), cyclophosphamide from Pharmedic, Lahore (Pakistan), levamisole from ICI (Pakistan), ketamine from Global Pharmaceuticals (Pakistan) and xylazine from mylab, Bahawalpur (Pakistan). .. ELISA kits for Interferon-γ (Catalog No: E-EL-R0009), Interleukin-2 (Catalog No: E-EL-R0013), Immunoglobulin type G (Catalog No: E-EL-R0518) and type M (Catalog No: E-EL-R3016) while colorimetric assay kits for malondialdehyde (MDA; E-BC-K025-M), total superoxide dismutase (T-SOD; E-BC-K020-M), glutathione peroxidase (GSH-Px; E-BC-K096-M) and catalase (CAT; E-BC-K031-M) were purchased from Elabscience Biotechnology, USA. ..

    Chloramphenicol Acetyltransferase Assay:

    Article Title: Pharmacological Role of Capparis decidua (Forssk.) Edgew in Preventing Cyclophosphamide-induced Myelosuppression and Modulating Innate and Adaptive Immune Response
    Article Snippet: All the chemicals utilized during research work were of analytical grade and obtained from different sources; ie dexamethasone, nigrosine and nylon pellets from Sigma Aldrich (USA), cyclophosphamide from Pharmedic, Lahore (Pakistan), levamisole from ICI (Pakistan), ketamine from Global Pharmaceuticals (Pakistan) and xylazine from mylab, Bahawalpur (Pakistan). .. ELISA kits for Interferon-γ (Catalog No: E-EL-R0009), Interleukin-2 (Catalog No: E-EL-R0013), Immunoglobulin type G (Catalog No: E-EL-R0518) and type M (Catalog No: E-EL-R3016) while colorimetric assay kits for malondialdehyde (MDA; E-BC-K025-M), total superoxide dismutase (T-SOD; E-BC-K020-M), glutathione peroxidase (GSH-Px; E-BC-K096-M) and catalase (CAT; E-BC-K031-M) were purchased from Elabscience Biotechnology, USA. ..



    Similar Products

    97
    PBL Assay universal type i ifn
    Universal Type I Ifn, supplied by PBL Assay, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Universal+Type+I+Interferon/pm42886769-59-6-14
    Average 97 stars, based on 1 article reviews
    universal type i ifn - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    Diaclone interferon gamma
    Interferon Gamma, supplied by Diaclone, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Human+IP-10+ELISA+Set/pm42903821-57-23-38
    Average 94 stars, based on 1 article reviews
    interferon gamma - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    Elabscience Biotechnology cytokines ifn γ
    Cytokines Ifn γ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Mouse+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pmc13683952-437-7-19
    Average 96 stars, based on 1 article reviews
    cytokines ifn γ - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Elabscience Biotechnology mouse ifn γ elisa kit
    HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
    Mouse Ifn γ Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Mouse+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pmc13682500-84-75-80
    Average 96 stars, based on 1 article reviews
    mouse ifn γ elisa kit - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    Elabscience Biotechnology human interferon γ ifn γ elisa kit
    HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
    Human Interferon γ Ifn γ Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Human+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pmc13682500-84-48-54
    Average 95 stars, based on 1 article reviews
    human interferon γ ifn γ elisa kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Elabscience Biotechnology ifn γ
    HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) <t>ELISA</t> detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.
    Ifn γ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Mouse+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pm42853894-435-9-19
    Average 96 stars, based on 1 article reviews
    ifn γ - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Elabscience Biotechnology ifnγ
    KU treatment mitigates EAE and reduces Th1 and Th17 cell proportions in mice. (A) Schematic timeline of EAE induction and KU administration (100 mg kg −1 , intragastric). Mice were immunized with MOG 35‐55 peptide, and KU or vehicle was administered from 11 to 21 dpi. (B) Line graph of clinical scores in the control (Ctrl), vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). (C) Disease incidence curves of EAE mice. (D) Cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord from the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (F) Inflammation and demyelination scores based on HE and LFB staining ( n = 6 per group). (G) The proportion of CD3 + CD4 + T cells in the CNS and spleen (SP) ( n = 3–4 per group). (H) Absolute counts of CD3 + and CD4 + T cells in the CNS of each group. (I) The proportion of CD4 + <t>IFNγ</t> + (Th1) cells in the CNS and SP. (J) The proportion of CD4 <t>+</t> <t>IL‐17A</t> + (Th17) cells in the CNS and SP. (K) Relative mRNA expression of T‐bet and RORγt in the spinal cord measured by qPCR. (L) ELISA detection of serum IFNγ and IL‐17A concentrations in each group. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle‐treated EAE.
    Ifnγ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Mouse+IFN-%CE%B3+(Interferon+Gamma)+ELISA+Kit/pmc13673060-218-7-12
    Average 96 stars, based on 1 article reviews
    ifnγ - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    PBL Assay ifn α2a
    KU treatment mitigates EAE and reduces Th1 and Th17 cell proportions in mice. (A) Schematic timeline of EAE induction and KU administration (100 mg kg −1 , intragastric). Mice were immunized with MOG 35‐55 peptide, and KU or vehicle was administered from 11 to 21 dpi. (B) Line graph of clinical scores in the control (Ctrl), vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). (C) Disease incidence curves of EAE mice. (D) Cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord from the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (F) Inflammation and demyelination scores based on HE and LFB staining ( n = 6 per group). (G) The proportion of CD3 + CD4 + T cells in the CNS and spleen (SP) ( n = 3–4 per group). (H) Absolute counts of CD3 + and CD4 + T cells in the CNS of each group. (I) The proportion of CD4 + <t>IFNγ</t> + (Th1) cells in the CNS and SP. (J) The proportion of CD4 <t>+</t> <t>IL‐17A</t> + (Th17) cells in the CNS and SP. (K) Relative mRNA expression of T‐bet and RORγt in the spinal cord measured by qPCR. (L) ELISA detection of serum IFNγ and IL‐17A concentrations in each group. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle‐treated EAE.
    Ifn α2a, supplied by PBL Assay, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/interferon/Human+Interferon+Alpha+A+-+Alpha+2a/bio_rxiv__64898__2026__10__12__758606-220-34-35
    Average 96 stars, based on 1 article reviews
    ifn α2a - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Migration, Analysis, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Flow Cytometry, Transwell Assay, Comparison, X-Ray Photoelectron Spectroscopy

    TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Enzyme-linked Immunosorbent Assay, Analysis, Concentration Assay, Transwell Migration Assay, Migration, Comparison

    The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Cell Function Assay, Flow Cytometry, Analysis, Enzyme-linked Immunosorbent Assay, Comparison

    Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Flow Cytometry, Analysis, Immune Cell, Tissue, Enzyme-linked Immunosorbent Assay, Comparison

    Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Biomarker Discovery, In Situ, Immunohistochemical staining, Staining, Analysis, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison

    HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: HCC cells promote MC migration and sustain MC proliferation. (A, B) Timer3.0 database analysis of SCF expression in tumors and correlation analysis between SCF and MCs; (C) ELISA detection of SCF levels in tumor tissues and adjacent tissues; (D) Correlation analysis between TAMC density and SCF concentration in HCC tumor tissues; (E): Flow cytometry identification of expanded hMCs at week 4; (F, G) Transwell assay for hMC migration capacity; (H, I) Flow cytometry for hMC proliferation; (J, K) Flow cytometry for hMC cell cycle. Data are presented as mean ± SD. Figure (B) used independent samples t ‐tests ( n = 59). (D) Spearman 's rank correlation analysis ( n = 59); (G/I/K), one‐way ANOVA with Tukey's post‐hoc multiple comparison test ( N = 3). * indicates p < 0.05; *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Migration, Analysis, Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay, Flow Cytometry, Transwell Assay, Comparison, X-Ray Photoelectron Spectroscopy

    TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: TAMCs recruit Tregs into the tumor microenvironment by secreting chemokines. (A) ELISA detection of CCL1, CCL5, CCL17, CCL22, and CCL28 secretion by TAMCs (after subtracting CCL1, CCL5, CCL17, CCL22, and CCL28 levels in TCCS); (B) ELISA detection of CCL17 levels in tumor tissues and adjacent tissues; (C) Correlation analysis between TAMCs and CCL17 concentration; D: Correlation analysis between Tregs and CCL17 concentration; (E, F) Transwell migration assay to assess Treg migration capacity. Data are presented as mean ± SD. (A, B), independent samples t ‐tests ( N = 3); (C, D) Spearman 's rank correlation analysis ( n = 59); (F), one‐way ANOVA and Tukey's multiple comparison test ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Enzyme-linked Immunosorbent Assay, Analysis, Concentration Assay, Transwell Migration Assay, Migration, Comparison

    The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: The TAMCs‐Tregs axis inhibits CD8 + T cell function. (A, B) Flow cytometry analysis of Treg‐mediated suppression of CD8 + T cell proliferation; (C–F) ELISA for Granzyme B, IFN‐γ, TNF‐α, and Perforin in supernatants from CD8 + T cell proliferation assays. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( N = 3). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Cell Function Assay, Flow Cytometry, Analysis, Enzyme-linked Immunosorbent Assay, Comparison

    Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: Combination therapy of anti‐PD‐1 antibody and CCR4 antagonists reshapes the tumor immune microenvironment in HCC. (A–F) Flow cytometry analysis of immune cell proportions (MCs, Tregs, CD8 + T cells) in tumor tissue; G–K: ELISA detection of Granzyme B, IFN‐γ, TNF‐α, Perforin, and CCL17 levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001.

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Flow Cytometry, Analysis, Immune Cell, Tissue, Enzyme-linked Immunosorbent Assay, Comparison

    Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

    Journal: Journal of Biochemical and Molecular Toxicology

    Article Title: Tumor‐Associated Mast Cells Drive Immunosuppression and Resistance to Anti‐PD‐1 Therapy in Hepatocellular Carcinoma Through CCL17/CCR4‐mediated Regulatory T‐Cell Recruitment

    doi: 10.1002/jbt.71127

    Figure Lengend Snippet: Validation of the synergistic antitumor efficacy of the triple‐drug therapy in an in situ Hepa1‐6 HCC model. (A) Representative images of in situ tumors; (B): Tumor volume in each group; (C) Tumor weight in each group; (D) Average ratio of liver weight to body weight; (E, F): Ki67 immunohistochemical staining and quantitative analysis; (G–L) Flow cytometry detection of the proportions of various immune cells (mast cells, Tregs, CD8 + T cells); (M) ELISA detection of Granzyme B, IFN‐γ, TNF‐α, and perforin levels. Data are presented as mean ± SD. One‐way ANOVA was performed, followed by Tukey's multiple comparison test for post‐hoc analysis ( n = 6).

    Article Snippet: The following kits were utilized: human SCF ELISA Kit (E‐EL‐H1299, Elabscience), human CCL1 ELISA kit (ab314600, Abcam), human CCL5 ELISA kit (ab174446, Abcam), human CCL17 ELISA kit (ab183366, Abcam), Human CCL22 ELISA Kit (ab242931, Abcam), Human CCL28 ELISA Kit (ab99988, Abcam), Human Granzyme B ELISA Kit (E‐EL‐H1617, Elabscience), Human Interferon‐γ (IFN‐γ) ELISA Kit (E‐EL‐H0108, Elabscience), Human TNF‐α ELISA Kit (E‐EL‐H0109, Elabscience), Human Perforin 1 ELISA Kit (E‐EL‐H1123, Elabscience), Mouse Granzyme B ELISA Kit (E‐EL‐M0594, Elabscience), Mouse IFN‐γ ELISA Kit (E‐EL‐M0048, Elabscience), Mouse TNF‐α ELISA Kit (E‐EL‐M3063, Elabscience), and Mouse Perforin ELISA Kit (E‐EL‐M0890, Elabscience).

    Techniques: Biomarker Discovery, In Situ, Immunohistochemical staining, Staining, Analysis, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Comparison

    KU treatment mitigates EAE and reduces Th1 and Th17 cell proportions in mice. (A) Schematic timeline of EAE induction and KU administration (100 mg kg −1 , intragastric). Mice were immunized with MOG 35‐55 peptide, and KU or vehicle was administered from 11 to 21 dpi. (B) Line graph of clinical scores in the control (Ctrl), vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). (C) Disease incidence curves of EAE mice. (D) Cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord from the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (F) Inflammation and demyelination scores based on HE and LFB staining ( n = 6 per group). (G) The proportion of CD3 + CD4 + T cells in the CNS and spleen (SP) ( n = 3–4 per group). (H) Absolute counts of CD3 + and CD4 + T cells in the CNS of each group. (I) The proportion of CD4 + IFNγ + (Th1) cells in the CNS and SP. (J) The proportion of CD4 + IL‐17A + (Th17) cells in the CNS and SP. (K) Relative mRNA expression of T‐bet and RORγt in the spinal cord measured by qPCR. (L) ELISA detection of serum IFNγ and IL‐17A concentrations in each group. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle‐treated EAE.

    Journal: Advanced Science

    Article Title: Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

    doi: 10.1002/advs.78358

    Figure Lengend Snippet: KU treatment mitigates EAE and reduces Th1 and Th17 cell proportions in mice. (A) Schematic timeline of EAE induction and KU administration (100 mg kg −1 , intragastric). Mice were immunized with MOG 35‐55 peptide, and KU or vehicle was administered from 11 to 21 dpi. (B) Line graph of clinical scores in the control (Ctrl), vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). (C) Disease incidence curves of EAE mice. (D) Cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord from the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (F) Inflammation and demyelination scores based on HE and LFB staining ( n = 6 per group). (G) The proportion of CD3 + CD4 + T cells in the CNS and spleen (SP) ( n = 3–4 per group). (H) Absolute counts of CD3 + and CD4 + T cells in the CNS of each group. (I) The proportion of CD4 + IFNγ + (Th1) cells in the CNS and SP. (J) The proportion of CD4 + IL‐17A + (Th17) cells in the CNS and SP. (K) Relative mRNA expression of T‐bet and RORγt in the spinal cord measured by qPCR. (L) ELISA detection of serum IFNγ and IL‐17A concentrations in each group. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle‐treated EAE.

    Article Snippet: The mouse serum was detected using the IFNγ and IL‐17A ELISA kits (Elabscience, E‐EL‐M0047, E‐EL‐M0048) according to the kit instructions.

    Techniques: Control, H&E Stain, Staining, Expressing, Enzyme-linked Immunosorbent Assay

    KU modulates gut microbiota to ameliorate EAE. (A) Alpha diversity (Shannon index) of gut microbiota in the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). Pair‐wise comparisons were performed using Wilcoxon rank‐sum test. (B) Principal coordinate analysis (PCoA) of gut microbiota based on Bray‐Curtis distance (pseudo‐ F = 30.12, R 2 = 0.741, p < 0.001); each dot represents an individual sample. (C) Stacked bar plot showing the relative abundance of gut microbiota at the family level in the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (D) Schematic timeline of ABX treatment and FMT and EAE induction: EAE mice received FMT from vehicle‐treated or KU‐treated donor mice (100 mg kg −1 , intragastric). (E) Clinical scores of FMT‐Vehicle and FMT‐KU groups ( n = 9 per group). (F) Disease incidence curves of EAE mice. (G) Statistical analysis of cumulative clinical scores and peak score. (H) Representative HE staining and LFB staining of spinal cord tissues from FMT‐Vehicle and FMT‐KU mice. (I) Inflammation score and demyelination score in the spinal cord ( n = 4 per group). (J) Flow cytometric plots of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP. (K) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 5 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. EAE mice that received FMT from vehicle‐treated donors.

    Journal: Advanced Science

    Article Title: Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

    doi: 10.1002/advs.78358

    Figure Lengend Snippet: KU modulates gut microbiota to ameliorate EAE. (A) Alpha diversity (Shannon index) of gut microbiota in the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups ( n = 8 per group). Pair‐wise comparisons were performed using Wilcoxon rank‐sum test. (B) Principal coordinate analysis (PCoA) of gut microbiota based on Bray‐Curtis distance (pseudo‐ F = 30.12, R 2 = 0.741, p < 0.001); each dot represents an individual sample. (C) Stacked bar plot showing the relative abundance of gut microbiota at the family level in the Ctrl, vehicle‐treated EAE, and KU‐treated EAE groups. (D) Schematic timeline of ABX treatment and FMT and EAE induction: EAE mice received FMT from vehicle‐treated or KU‐treated donor mice (100 mg kg −1 , intragastric). (E) Clinical scores of FMT‐Vehicle and FMT‐KU groups ( n = 9 per group). (F) Disease incidence curves of EAE mice. (G) Statistical analysis of cumulative clinical scores and peak score. (H) Representative HE staining and LFB staining of spinal cord tissues from FMT‐Vehicle and FMT‐KU mice. (I) Inflammation score and demyelination score in the spinal cord ( n = 4 per group). (J) Flow cytometric plots of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP. (K) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 5 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. EAE mice that received FMT from vehicle‐treated donors.

    Article Snippet: The mouse serum was detected using the IFNγ and IL‐17A ELISA kits (Elabscience, E‐EL‐M0047, E‐EL‐M0048) according to the kit instructions.

    Techniques: Analysis, H&E Stain, Staining

    KU ameliorates EAE in an A. muciniphila ‐dependent manner. (A) Heatmap showing the relative abundance of the top 10 gut microbial species in the Ctrl, vehicle‐treated EAE, and KU‐treated groups ( n = 8 per group). (B) Linear discriminant analysis effect size (LEfSe) analysis was performed to screen differentially abundant microbial taxa across the three groups. Taxa with an LDA score > 3 were defined as potential microbial biomarkers with statistical significance. (C) Schematic timeline of ABX pretreatment, KU administration, A. muciniphila supplementation, and EAE induction. (D) Clinical scores of EAE, EAE+ABX, EAE+ABX+KU, and EAE+ABX+KU+ A. muciniphila ( n = 8 per group). (E) Cumulative clinical scores and peak score in each group. (F) Representative HE staining and LFB staining of the spinal cord. (G) Spinal cord inflammation score and demyelination score ( n = 4 per group). (H) Flow cytometric plots of CD4 + IFNγ + (Th1) cells in the CNS and SP of each group. (I) Quantification of CD4 + IFNγ + cell percentages in the CNS and SP ( n = 4 per group). (J) Flow cytometric plots of CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (K) Quantification of CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, p > 0.05.

    Journal: Advanced Science

    Article Title: Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

    doi: 10.1002/advs.78358

    Figure Lengend Snippet: KU ameliorates EAE in an A. muciniphila ‐dependent manner. (A) Heatmap showing the relative abundance of the top 10 gut microbial species in the Ctrl, vehicle‐treated EAE, and KU‐treated groups ( n = 8 per group). (B) Linear discriminant analysis effect size (LEfSe) analysis was performed to screen differentially abundant microbial taxa across the three groups. Taxa with an LDA score > 3 were defined as potential microbial biomarkers with statistical significance. (C) Schematic timeline of ABX pretreatment, KU administration, A. muciniphila supplementation, and EAE induction. (D) Clinical scores of EAE, EAE+ABX, EAE+ABX+KU, and EAE+ABX+KU+ A. muciniphila ( n = 8 per group). (E) Cumulative clinical scores and peak score in each group. (F) Representative HE staining and LFB staining of the spinal cord. (G) Spinal cord inflammation score and demyelination score ( n = 4 per group). (H) Flow cytometric plots of CD4 + IFNγ + (Th1) cells in the CNS and SP of each group. (I) Quantification of CD4 + IFNγ + cell percentages in the CNS and SP ( n = 4 per group). (J) Flow cytometric plots of CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (K) Quantification of CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001; ns, p > 0.05.

    Article Snippet: The mouse serum was detected using the IFNγ and IL‐17A ELISA kits (Elabscience, E‐EL‐M0047, E‐EL‐M0048) according to the kit instructions.

    Techniques: Analysis, H&E Stain, Staining

    IAAld alleviates EAE and reduces Th1 and Th17 cell proportions. (A) Schematic timeline of EAE induction and IAAld administration ( n = 8 per group). (B) Clinical scores of vehicle‐treated EAE, EAE+IAAld 40 mg/kg/day (IAAld 40), and EAE+IAAld 80 mg/kg/day (IAAld 80) groups. (C) Disease incidence curves of EAE mice with different doses of IAAld treatment. (D) Quantification of cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord tissues from the vehicle‐treated EAE, IAAld 40, and IAAld 80 groups. (F) Spinal cord inflammation score and demyelination score ( n = 3 per group). (G) Flow cytometric plots of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (H) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Advanced Science

    Article Title: Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

    doi: 10.1002/advs.78358

    Figure Lengend Snippet: IAAld alleviates EAE and reduces Th1 and Th17 cell proportions. (A) Schematic timeline of EAE induction and IAAld administration ( n = 8 per group). (B) Clinical scores of vehicle‐treated EAE, EAE+IAAld 40 mg/kg/day (IAAld 40), and EAE+IAAld 80 mg/kg/day (IAAld 80) groups. (C) Disease incidence curves of EAE mice with different doses of IAAld treatment. (D) Quantification of cumulative clinical scores and peak score in each group. (E) Representative HE staining and LFB staining of spinal cord tissues from the vehicle‐treated EAE, IAAld 40, and IAAld 80 groups. (F) Spinal cord inflammation score and demyelination score ( n = 3 per group). (G) Flow cytometric plots of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (H) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP ( n = 4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: The mouse serum was detected using the IFNγ and IL‐17A ELISA kits (Elabscience, E‐EL‐M0047, E‐EL‐M0048) according to the kit instructions.

    Techniques: H&E Stain, Staining

    IAAld treatment mitigates EAE in an AhR‐dependent manner. (A) Relative mRNA expression levels of Ahr, Cyp1a1, and Cyp1b1 in the spinal cord of EAE mice treated with vehicle, IAAld 40, or IAAld 80 groups. (B) Schematic timeline depicting the experimental protocol for EAE induction, followed by administration of IAAld (80 mg/kg/day) and AhR inhibitor (AhRi; SR1, 50 mg/kg/day). (C) Clinical scores for EAE mice treated with vehicle, IAAld, and IAAld+AhRi groups ( n = 6 per group). (D) Disease incidence curves for EAE mice over time. (E) Quantification of cumulative clinical scores and peak score for each group. (F) Representative HE and LFB staining of spinal cord tissues for assessment of inflammation and demyelination, respectively. (G) Quantification of spinal cord inflammation and demyelination scores ( n = 3 per group). (H) Representative flow cytometry plots indicating the percentages of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (I) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP across groups ( n = 3–4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Journal: Advanced Science

    Article Title: Gut Microbiota‐Derived Indole‐3‐Acetaldehyde Contributes to the Disease‐Alleviating Effects of Kurarinone in Experimental Autoimmune Encephalomyelitis

    doi: 10.1002/advs.78358

    Figure Lengend Snippet: IAAld treatment mitigates EAE in an AhR‐dependent manner. (A) Relative mRNA expression levels of Ahr, Cyp1a1, and Cyp1b1 in the spinal cord of EAE mice treated with vehicle, IAAld 40, or IAAld 80 groups. (B) Schematic timeline depicting the experimental protocol for EAE induction, followed by administration of IAAld (80 mg/kg/day) and AhR inhibitor (AhRi; SR1, 50 mg/kg/day). (C) Clinical scores for EAE mice treated with vehicle, IAAld, and IAAld+AhRi groups ( n = 6 per group). (D) Disease incidence curves for EAE mice over time. (E) Quantification of cumulative clinical scores and peak score for each group. (F) Representative HE and LFB staining of spinal cord tissues for assessment of inflammation and demyelination, respectively. (G) Quantification of spinal cord inflammation and demyelination scores ( n = 3 per group). (H) Representative flow cytometry plots indicating the percentages of CD4 + IFNγ + (Th1) and CD4 + IL‐17A + (Th17) cells in the CNS and SP of each group. (I) Quantification of CD4 + IFNγ + and CD4 + IL‐17A + cell percentages in the CNS and SP across groups ( n = 3–4 per group). Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

    Article Snippet: The mouse serum was detected using the IFNγ and IL‐17A ELISA kits (Elabscience, E‐EL‐M0047, E‐EL‐M0048) according to the kit instructions.

    Techniques: Expressing, Staining, Flow Cytometry